A further post hoc analysis of the ATHOS-3 study suggested a benefit in patients with acute respiratory distress syndrome (ARDS), with improved oxygenation in the Ang II-treated patients and a trend towards lower mortality [30]. This evidence concerns the gene AGT and acute respiratory distress syndrome.